<table>
<thead>
<tr>
<th>Originator</th>
<th>Pharmaceutical</th>
<th>Phase</th>
<th>Marketed</th>
<th>Route</th>
<th>Market Licensee</th>
<th>Collaborator</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis</td>
<td>Large Pharma</td>
<td>II/III</td>
<td>PO</td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>China</td>
<td>Large Pharma</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>Italy</td>
<td>Pharmaceutical</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>Novartis</td>
<td>Pharmaceutical</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>Takeda</td>
<td>Large Pharma</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>Japan</td>
<td>Large Pharma</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>Novartis</td>
<td>Pharmaceutical</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>Takeda</td>
<td>Large Pharma</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
<tr>
<td>Japan</td>
<td>Large Pharma</td>
<td>PO</td>
<td></td>
<td></td>
<td>Japan, South Korea, China</td>
<td>Takeda</td>
<td>Marketed</td>
</tr>
</tbody>
</table>

**Acetylcholinesterase inhibitors**

- Donepezil is a reversible inhibitor of acetylcholinesterase (AChE) primarily for the treatment of age-related cognitive decline in Alzheimer's disease (AD).
- Rivastigmine is a reversible, noncompetitive inhibitor of acetylcholinesterase and butyrylcholinesterase (BuChE) primarily for the treatment of mild-to-moderate dementia associated with Parkinson's disease.

**EGb 761**

- EGb 761 is a standardised and patented extract of Ginkgo biloba, a central nervous system (CNS) molecular imaging agent for the early diagnosis of Alzheimer's disease (AD). AChE inhibitor, used for the treatment of Alzheimer's disease (Diagnosis).

**Cerebrolysin®**

- Cerebrolysin® is a peptidergic drug that has been shown to accelerate neural growth and is a putative nootropic agent and a selective, competitive AChE inhibitor. It is primarily used in the treatment of age-related cognitive decline in Alzheimer's disease (Diagnosis). The precise mechanism of action for idebenone is unknown.

**Huperzine A**

- Huperzine A is an alkaloid isolated from the club moss Huperzia serrata, which is widely used in China. It is an anticholinesterase agent in anaesthesia and in the treatment of Alzheimer's disease. The anticholinesterase agent tacrine has been shown to accelerate neural growth and is primarily used in the treatment of age-related cognitive decline in Alzheimer's disease (AD). AChE inhibitor, used for the treatment of Alzheimer's disease (Diagnosis). The precise mechanism of action for idebenone is unknown.

**Namenda XR™**

- Namenda XR™ is an acetylcholinesterase inhibitor (AChE) used for the treatment of Alzheimer's disease (Diagnosis).

**Razadyne™ ER**

- Razadyne™ ER is used for the treatment of Alzheimer's disease (Diagnosis).

**Alzheimer's Disease (Registered & Launched)**

- Alzheimer's disease (In volunteers) is a phase of Alzheimer's disease research.
- Alzheimer's disease (Diagnosis) is a phase of Alzheimer's disease research.
- Alzheimer's disease (Prevention: Patients with mild cognitive impairment) is a phase of Alzheimer's disease research.
- Alzheimer's disease (In patients: Delirium) is a phase of Alzheimer's disease research.
- Alzheimer's disease (In patients: Vascular disorders) is a phase of Alzheimer's disease research.
- Alzheimer's disease (In patients: Cancer treatment) is a phase of Alzheimer's disease research.
- Alzheimer's disease (In children) is a phase of Alzheimer's disease research.

**Attention-deficit hyperactivity disorder**

- Attention-deficit hyperactivity disorder (In children) is a phase of attention-deficit hyperactivity disorder research.

**Diabetic neuropathies**

- Diabetic neuropathies is a phase of diabetic neuropathies research.

**Free radical scavengers**

- Free radical scavengers (In patients: Peripheral nervous system diseases) is a phase of free radical scavengers research.

**Platelet aggregation inhibitors**

- Platelet aggregation inhibitors (In patients: Delirium) is a phase of platelet aggregation inhibitors research.
- Platelet aggregation inhibitors (In patients: Vascular disorders) is a phase of platelet aggregation inhibitors research.
- Platelet aggregation inhibitors (In patients: Cancer treatment) is a phase of platelet aggregation inhibitors research.
- Platelet aggregation inhibitors (In patients: Peripheral nervous system diseases) is a phase of platelet aggregation inhibitors research.
- Platelet aggregation inhibitors (In patients: Attention-deficit hyperactivity disorder) is a phase of platelet aggregation inhibitors research.

**Mild cognitive impairment**

- Mild cognitive impairment is a phase of mild cognitive impairment research.

**Peripheral nervous system diseases**

- Peripheral nervous system diseases is a phase of peripheral nervous system diseases research.

**Autistic disorder (In children)**

- Autistic disorder (In children) is a phase of autistic disorder research.